PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$110.60
as of September 15, 2026 -
YTD RETURNS8.74%
as of September 15, 2026 -
Total Net Assets$999.60M
as of September 15, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 2.45 | 8.50 | 11.15 | 29.87 | 13.65 | 10.41 | 8.78 | 10.31 |
| PPH (Market Price) | 2.43 | 8.57 | 11.13 | 29.92 | 13.65 | 10.41 | 8.79 | 10.39 |
| MVIS US Listed Pharmaceutical 25 Index | 2.46 | 8.50 | 10.94 | 29.69 | 13.30 | 10.05 | 8.53 | 10.12 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 09/14/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
18.90 |
189,889,008 |
|
MRK |
Merck & Co Inc |
10.86 |
109,118,592 |
|
NVS |
Novartis Ag |
9.28 |
93,200,300 |
|
PFE |
Pfizer Inc |
5.11 |
51,315,070 |
|
BMY |
Bristol-Myers Squibb Co |
4.89 |
49,171,815 |
|
MCK |
Mckesson Corp |
4.89 |
49,153,040 |
|
NVO |
Novo Nordisk A/S |
4.79 |
48,099,802 |
|
ABBV |
Abbvie Inc |
4.69 |
47,067,555 |
|
JNJ |
Johnson & Johnson |
4.50 |
45,163,345 |
|
GSK |
Gsk Plc |
4.15 |
41,718,076 |
|
SNY |
Sanofi Sa/France |
4.00 |
40,221,896 |
|
COR |
Cencora Inc |
3.81 |
38,264,495 |
|
AZN |
Astrazeneca Plc |
3.68 |
37,016,245 |
|
TEVA IT |
Teva Pharmaceutical Industries Ltd |
3.44 |
34,564,337 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
3.28 |
32,956,150 |
|
HLN |
Haleon Plc |
3.06 |
30,765,086 |
|
ZTS |
Zoetis Inc |
2.12 |
21,279,432 |
|
VTRS |
Viatris Inc |
1.13 |
11,361,987 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.09 |
10,905,072 |
|
AXSM |
Axsome Therapeutics Inc |
0.67 |
6,718,312 |
|
CORT |
Corcept Therapeutics Inc |
0.64 |
6,408,488 |
|
ELAN |
Elanco Animal Health Inc |
0.33 |
3,286,073 |
|
OGN |
Organon & Co |
0.23 |
2,284,505 |
|
BHC |
Bausch Health Cos Inc |
0.12 |
1,162,552 |
|
PRGO |
Perrigo Co Plc |
0.08 |
780,766 |
|
-USD CASH- |
-- |
0.00 |
9,729 |
|
-- |
Other/Cash |
0.27 |
2,691,494 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 08/31/2026
-
Sector
% of Net Assets -
Health Care
99.79 -
Other/Cash
0.21
Country Weightings (%) as at 08/31/2026
-
Country
% of Net Assets -
United States
63.70 -
United Kingdom
10.90 -
Switzerland
9.98 -
Denmark
4.91 -
France
4.03 -
Israel
3.15 -
Japan
3.12 -
Other/Cash
0.21
Fees
Distributions
as of 09/15/2026
Quarterly
1.88%
2.26%
1.96%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency